OncoTherapy Science, Inc.
Notice of Joint Research Agreement by our Consolidated Subsidiary with The University of Tokyo and Sanyo Kagaku Co., Ltd.
CPM has entered into a joint research agreement with The University of Tokyo and Sanyo Kagaku on liquid biopsy-based monitoring of solid tumor treatment. The impact on the FY2027 performance is expected to be minimal.
Key Figures
- Joint research agreement signed
- Target: patients with solid tumors, ctDNA analysis, treatment monitoring
- Impact period: minimal impact on FY2027
AI要約
Overview of the Joint Research
CPM has concluded a joint research agreement with The University of Tokyo and Sanyo Kagaku to clinically validate a novel cancer genetic panel using liquid biopsy targeting solid tumors. This study will analyze circulating tumor DNA to verify test performance and evaluate and predict therapeutic effectiveness in a clinical setting.
Background and Purpose of the Joint Research
Liquid biopsy is less invasive than tissue biopsy and enables repeated testing while providing real-time insight into overall patient condition. This panel aims to comprehensively analyze common genetic mutations across solid tumors, validating test performance and predicting treatment outcomes in real clinical practice.
OncoTherapy Science, Inc.
Company overview · Stock price · Financial data · All IR
